Matthew Perry Investigation: Can Ketamine Kill Someone?

Updated Aug 17, 2024 | 12:00 PM IST

SummaryNew evidence has come up in the investigation of Matthew Perry, 'Friends' Chandler Bing's death on October 28. This evidence points to an overdose of ketamine. What is ketamine and how does it affect you? Read now.
Matthew Perry Investigation Can Ketamine Kill Someone

Credits: IMDb

“I'm not great at the advice. Can I interest you in a sarcastic comment?”

Friends Actor Matthew Perry

This is what ‘Friends’ actor Matthew Perry’s character Chandler Bing was known for. He was known for being funny. However, he had his own struggles in his personal life and those struggles were acute depression. He was treating it with ketamine infusion therapy which is legal in the US and the UK.

What is Ketamine infusion therapy?

Ketamine is an anaesthetic used to treat depression, anxiety and pain under supervised and controlled medical settings. However, it does have its side effects, which can lead to distortion of sight, sound and time. It can also produce calming and relaxing effects.

Ketamine increases a person’s heart rate and blood pressure. If overdosed, it can leave users confused and agitated and can cause them to hurt themselves without even realising it. It can also lead to liver damage and bladder problems.

However, when used in moderation and under the supervision of medical doctors, it can treat depression where traditional antidepressants have failed.

Prof Rupert McShane, a University of Oxford psychiatrist who runs an NHS ketamine treatment clinic told BBC that ketamine “probably turns off the area of the brain that is involved in disappointment.”

Can Ketamine Infusion Therapy Kill Someone?

In simple terms, it cannot, be if the dosage is given in a controlled setting and as prescribed. Ketamine infusion therapy uses drugs in small doses than those used for anaesthesia. It acts faster than traditional anti-depressants, but the effects also wear off way quickly. Which is why it is important to monitor patients’ mental state for relapsing back into depression and discouraging them from overdosing on it.

There are ways of giving people ketamine. One of the ways is through “infusing”, which means to use an IV drip. However, injections, nasal sprays and capsules are also methods used to give people ketamine.

Since the dosage of ketamine used in the infusion treatment is small, it being the reason of actor Perry’s death was ruled out. The medical examiner also noted that Perry’s last ketamine infusion therapy session happened more than a week before his death, which means by the time he had died, it must have worn off.

So, What Happened To Perry?

Though Perry’s last session was more than a week before, his post-mortem showed that his blood contained a high concentration of ketamine. He had died of the “acute effects” of ketamine.

If it was not his session, then how did he get ketamine?

Prosecutors alleged that his assistant gave him at least 27 shots of ketamine in four days before his death, reported BBC.

Perry has been open about his personal struggles and this is what the doctors and dealers used against him. Martin Estrada, the US attorney for California’s Central District told the BBC that people took advantage of his condition. They charged him 165 times more than what vials of ketamine cost.

Names that have come up include Dr Salvador Plasencia, drug dealers “Ketamine Queen” aka Jasveen Sangha and Eric Fleming, and Perry’s live-in assistant Kenneth Iwamasa.

Who Are These Names And What Did They Do?

Ketamine Queen or Sangha supplied drugs that led to Perry’s death. Her home was a “drug-selling emporium,” said Estrada. More than 80 vials of ketamine, and thousands of pills including methamphetamine, cocaine and Xanax were allegedly found in her house known as the “Sangha Stash House.”

Sangha is known to deal with high-end celebs and was a “major source of supply for ketamine to others as well as Perry,” said Estrada.

Dr Plasencia called Perry a “moron” while charging him $2,000 for vials that cost only $12. He sold Perry 20 vials of ketamine between September and October 2023, costing $55,000.

He was the one who taught Iwamasa, who had no medical knowledge to inject the drug. This is after he knew that “Perry’s ketamine addiction was spiralling out of control,” as per what the investigators told the BBC.

Another dealer Fleming was told by Sangha to “delete all our messages.” While Fleming pleaded guilty to conspiring to distribute drugs unlawfully, he also allegedly messaged Sangha: “Please call...Got more info and want to bounce ideas off you. I’m 90% sure everyone is protected. I never dealt with [Perry] only his assistant. So the assistant was the enabler.”

The court documents also revealed that he asked Sangha on whether the ketamine stays in your system or “is it immediately flushed out.”

Dr Pepper, Bots, Cans

The people who allegedly exploited Perry used coded language for ketamine and called it “Dr Pepper”, “bots”, or “cans.”

Selling overpriced drugs, taking advantage of Perry’s mental condition and falsifying medical records to make the drugs given to him look legitimate by Dr Plasencia is what took Perry’s life.

Iwamasa is said to have administered more than 20 shots of ketamine and three on the day Perry died. Whereas ketamine is only administered by a physician. Authorities also found that weeks before Perry’s death, Dr Plasencia allegedly bought 10 vials of ketamine and intended to sell to Perry.

He also injected Perry with a large dose, two days later. This caused him to “freeze up” and spiked his blood pressure.

When I Die, I Want Helping Others To Be The First Thing That’s Mentioned

Perry had always been open about his drug addictions, struggles with alcohol and his depression. He said that his openness would help others who are also struggling and wanted to be remembered by his quote which also is on the homepage of the Mattew Perry Foundation that helps others struggling with the disease of addiction: “When I die, I want helping others to be the first thing that’s mentioned.”

Five arrests have been made in the case so far.

End of Article

H5N1 Bird Flu Reaches New Zealand; 12 Human Infections Reported Worldwide

Updated Jul 17, 2026 | 01:00 AM IST

SummaryThe infected bird, a brown skua, was found on Petone Beach in Wellington on July 10 and tested positive for H5N1. The detection comes weeks after Australia began reporting H5N1 cases in wild birds, with the country now confirming 14 infections.
H5N1 Bird Flu Reaches New Zealand; 12 Human Infections Reported Worldwide

Credit: iStock

The highly pathogenic avian influenza (H5N1) virus has been detected in New Zealand for the first time, raising concerns for the country's native birds.

NZ health authorities confirmed the virus in a wild seabird while stressing that there is currently no evidence of wider transmission within the country.

The infected bird, a brown skua, was found on Petone Beach in Wellington on July 10 and tested positive for H5N1. The detection comes just weeks after the virus was confirmed in Australia, a development that had prompted New Zealand authorities to prepare for its possible arrival. the country now confirming 14 infections.now confirming 14 infections.

New Zealand Biosecurity Minister Andrew Hoggard said the case appears to be isolated.

"There is no evidence of any mass mortality in wildlife or transmission between wild birds in New Zealand," Hoggard said, while urging the public to remain vigilant and report sick or dead birds.

Health and wildlife officials have launched enhanced surveillance to determine whether additional infections emerge in wild bird populations.

Global Human Cases Remain Rare but Serious

Also read: Australia’s H5N1 Detection Marks End Of Last Virus-Free Continent

The latest H5N1 detection comes as the US Centers for Disease Control and Prevention (CDC), in June, reported identifying 12 human H5N1 infections outside the US between August 4, 2025, and June 10, 2026.

According to the CDC, the cases were reported in:

  • Bangladesh
  • Cambodia
  • India
Of the 12 infections, three were fatal—one in Bangladesh and two in Cambodia.

Importantly, the CDC said no person-to-person transmission was identified in any of these cases. Most infections occurred after direct or close contact with infected poultry or other sick animals.

The agency said the international cases do not change its assessment that the risk of H5N1 to the general public remains low, but they reinforce the need for continued monitoring.

Cambodia's Ministry of Health on July 9 confirmed the fifth H5N1 human infection of 2026, in a 9-month-old girl from Phnom Penh. It is the 39th case in the country in the last three years.

Why Surveillance Matters

The CDC noted that sporadic human infections are expected as H5N1 continues circulating widely among wild birds and poultry across multiple regions.

"While rare, these H5N1 bird flu cases in humans underscore the need for strong systems to monitor and prepare for influenza," the agency said, calling for robust surveillance and testing.

Read More: Cyclosporiasis Outbreak: US Probes Taco Bell Link; CDC Reviews Over 5,100 Cases

Bird Flu Viruses That Can Infect Humans

Scientists have identified five avian influenza virus subtypes capable of infecting humans:

  • A(H5)
  • A(H6)
  • A(H7)
  • A(H9)
  • A(H10)
Among these, A(H5), A(H7), and A(H9) viruses have caused the largest number of human infections globally.

Although the overall risk to the public remains low, health experts called for continued surveillance in birds, animals, and humans, which will be essential as H5N1 continues to spread geographically.

How To Protect Yourself

Health authorities recommend the following precautions:

  • Avoid direct contact with sick or dead wild birds and other animals whenever possible.
  • Observe wildlife from a safe distance.
  • Wear appropriate personal protective equipment (PPE) if handling sick or dead birds or animals is unavoidable.
  • Avoid touching surfaces contaminated with bird droppings, saliva, mucus, litter, or bedding from infected or suspected animals.
  • Do not consume raw milk or raw milk products, particularly from animals suspected or confirmed to be infected with avian influenza.
  • Report sick or dead birds to local authorities if encountered.

End of Article

Botulism Cases Surge in UK: MHRA Issues Botox Safety Warning Over Rare Life-Threatening Side Effect

Updated Jul 16, 2026 | 08:55 PM IST

SummaryBotulinum toxin medicines are widely used for cosmetic procedures, such as reducing facial wrinkles, as well as for treating conditions including muscle spasms, excessive sweating (hyperhidrosis), and an overactive bladder.
Botulism Cases Surge in UK: MHRA Issues Botox Safety Warning Over Rare Life-Threatening Side Effect

Credit: iStock

Amid reports of rare botulism cases in the UK, the country's Medicines and Healthcare products Regulatory Agency (MHRA) has issued a safety warning for all botulinum toxin type A products, including Botox and other cosmetic injectables.

The regulator said cases of iatrogenic botulism—botulism caused by medical treatment—have been reported following both therapeutic and cosmetic use of botulinum toxin products when the toxin spreads beyond the intended injection site.

"Patients should seek immediate medical advice if they experience signs and symptoms," the MHRA said.

Why Are Botulinum toxin At Risk?

Botulinum toxin medicines are widely used for cosmetic procedures, such as reducing facial wrinkles, as well as for treating conditions including muscle spasms, excessive sweating (hyperhidrosis), and an overactive bladder.

While these medicines are considered safe when used correctly, the MHRA warned that, in very rare cases, the toxin can spread beyond the injection site and cause botulism—a serious and potentially life-threatening condition.

To improve awareness, the regulator has worked with manufacturers to update product information and patient leaflets to more clearly highlight the risk of iatrogenic botulism.

Also read: GLP-1 Weight-Loss Drugs Show Promise for 17 Million With Binge Eating Disorder, Suggests Study

Symptoms Can Appear Up to Four Weeks Later

The MHRA warned that symptoms may not appear immediately after treatment. They can develop within days or even up to four weeks after receiving a botulinum toxin injection.

Patients are advised to seek immediate medical attention if they experience:

  • Difficulty swallowing
  • Slurred speech or difficulty talking
  • Difficulty breathing or shortness of breath
  • Muscle weakness
Severe cases may require intensive care and mechanical ventilation.

Who Is at Higher Risk?

According to the MHRA, the risk of serious side effects may be higher in:

  • People with underlying neurological disorders
  • Those with a history of difficulty swallowing (dysphagia)
  • Those with a history of aspiration (inhaling food or fluids into the lungs)
  • Patients receiving high doses of botulinum toxin
  • Procedures performed outside licensed indications or at unapproved injection sites
  • Use of counterfeit or unlicensed botulinum toxin products

Health officials say early recognition of symptoms is critical, as prompt treatment can help prevent serious complications.

"While botulism is a rare infection, it can be serious. There are effective treatments available, and we recommend seeking immediate medical advice if you have had a recent treatment and are experiencing symptoms such as difficulty swallowing," said Dr. Martin Bewley, Consultant in Health Protection at the UK Health Security Agency (UKHSA).

Dr. Alison Cave, Chief Safety Officer at the MHRA, recommended that healthcare professionals and patients be aware of the symptoms of botulism and act quickly if they arise. Importantly, the expert "strongly urged the public to avoid unlicensed products and seek treatment only from appropriately qualified practitioners."

What Is Botulism?

Botulism is a rare but serious illness caused by a toxin produced by the bacterium Clostridium botulinum. The toxin attacks the nervous system and can lead to paralysis, breathing difficulties, and, in severe cases, death if not treated promptly.

Because it can rapidly affect the muscles involved in breathing, botulism is considered a medical emergency.

End of Article

Lipfendra: Merck's New FDA-Approved Pill That Cuts 'Bad' Cholesterol Better Than Statins

Updated Jul 16, 2026 | 08:10 PM IST

Summary​Lipfendra has been approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
Lipfendra: Merck's New FDA-Approved Pill That Cuts 'Bad' Cholesterol Better Than Statins

Credit: AI generated image

The US Food and Drug Administration (FDA) has approved a once-daily pill that can lower low-density lipoprotein (LDL), commonly known as "bad" cholesterol, a major risk factor for heart disease.

Developed by Merck, enlicitide, which will be marketed as Lipfendra, is the first FDA-approved oral PCSK9 inhibitor for reducing LDL cholesterol.

Lipfendra has been approved as an adjunct to diet and exercise to reduce LDL cholesterol in adults with primary hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).

The approval is based on two Phase 3 clinical trials showing that Lipfendra can reduce LDL cholesterol to 50–60 mg/dL or even lower in many patients.

"Results from these Phase 3 trials showed treatment with Lipfendra resulted in reductions across other atherogenic lipoproteins associated with atherosclerotic cardiovascular disease (ASCVD) risk, including non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B (ApoB)," Merck said.

High LDL cholesterol is a major risk factor for atherosclerotic cardiovascular disease (ASCVD), the leading cause of death globally.

"In two Phase 3 trials, LIPFENDRA led to impressive reductions in LDL-C. Now, for the first time, patients have an oral PCSK9 inhibitor for LDL lowering," said Dr. Ann Marie Navar, lead author of the clinical trial and associate professor at the University of Texas Southwestern Medical Center.

Also read: Spinal Muscular Atrophy: England to Roll Out Nationwide Newborn Screening From 2027

How Does Lipfendra Work?

Lipfendra is a 20 mg once-daily tablet that works by blocking PCSK9, a protein that regulates LDL receptors in the liver.

Normally, PCSK9 reduces the number of LDL receptors available to remove cholesterol from the bloodstream. By inhibiting this protein, Lipfendra allows more LDL receptors to remain active, enabling the liver to clear more LDL cholesterol from the blood.

Unlike statins, which lower cholesterol by blocking an enzyme the liver uses to produce cholesterol, Lipfendra targets the PCSK9 pathway. It is also the first oral medicine in this class, whereas existing PCSK9 inhibitors are administered as injections.

What Did the Clinical Trials Show?

The FDA approval was supported by two Phase 3 studies, including a 24-week trial involving 2,912 participants, which demonstrated significant reductions in LDL cholesterol.

The studies found that:

  • Lipfendra lowered LDL cholesterol by up to 60%.
  • Many participants achieved LDL levels of 50–60 mg/dL or lower.
  • The drug also reduced non-HDL cholesterol and ApoB, two additional markers associated with cardiovascular risk.
  • Side effects were similar to those seen with placebo.
Read More: Meet Erica Schwartz: Trump's CDC Nominee Who Pledges to 'Never Betray Science'

The cholesterol-lowering effect was comparable to that seen with injectable PCSK9 inhibitors.

Merck is now conducting a cardiovascular outcomes trial to determine whether Lipfendra also lowers the risk of heart attacks, strokes and cardiovascular death, as injectable PCSK9 inhibitors have previously been shown to do.

Lipfendra: How Much Does It Cost?

Merck said Lipfendra will be available in the United States within the next few weeks. The company has set a list price of $315 for a 30-day supply, according to Merck spokeswoman Julie Cunningham.

Who Could Benefit From Lipfendra?

Lipfendra is intended for adults with hypercholesterolemia, a condition characterized by elevated LDL cholesterol that can lead to plaque buildup in the arteries.

The drug may particularly benefit:

  • Adults with primary hypercholesterolemia.
  • People with heterozygous familial hypercholesterolemia (HeFH).
  • Patients who need additional LDL lowering despite diet, exercise or statin therapy.
  • Individuals looking for an oral alternative to injectable PCSK9 inhibitors.

End of Article